Expanding the utility of cellular therapies to additional disease states as well as standardizing clinical management of patients treated with CAR-T cells and developing novel therapies to optimize clinical outcomes for patients with acute myeloid leukemia.
Retrovirus-based gene transfer into hematopoietic stem cells has emerged as a viable treatment for genetic, malignant and infectious diseases with the potential to significantly decrease global disease burden.
Clinical and research focus on improving outcome of hematopoietic cell transplantation (HCT). Allogeneic HCT has the potential to provide long-term survival and even cure in patients with hematological malignancies.
Laboratory studies are focused on preventing graft-versus-host-disease for children undergoing allogeneic stem cell transplants, the discovery of leukemia associated minor histocompatibility antigens and the development of adoptive T cell immunotherapy.
Research focus is on acute and chronic graft-vs.-host disease (GVHD), the amelioration of long-term complications associated with GVHD therapies, and the prevention of relapse after transplant in the context of continued immunosuppressive therapy.
Developing novel therapies and risk-stratification methods for adults with acute lymphoblastic leukemia. Radioimmunotherapy-based conditioning regimens for hematopoietic cell transplantation in adults with high-risk lymphoma.
Research is centered on 1) understanding the factors associated with successful adoptive transfer of immune T cells and improving the outcomes of both native and gene-modified T cells targeting viral and tumor antigens, 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T-cell products so as to better eliminate tumor targets and 3) clinical strategies to modulate the host immune environment as a means to optimally activate T cells in humans.
Pulmonologist and critical care specialist who sees patients with pulmonary complications after hematopoietic stem cell transplantation (HCT), including infectious pneumonia and non-infectious pulmonary complications.
Novel therapeutics in prostate and bladder cancer, correlative science/translational studies in clinical trials , clinical and molecular predictors of response to cancer therapies and circulating microRNA biomarkers for prostate cancer.
The Clurman Lab studies how cell division is regulated in normal cells, and how abnormal control of cell division leads to cancer. They hope to use these mechanistic insights into tumor formation to develop new cancer treatment strategies.
Focus is on colorectal, pancreas and liver cancers and other gastrointestinal malignancies. Research includes the assessment of genes affecting the progression of cancer, identifying new biomarkers, and the characterization of colorectal cancer Type X.
Translational research focused on melanoma, non-melanoma skin cancers and sarcomas. Investigating anti-neoplastic agents in pre-clinical models, both alone and in combination with conventional chemotherapy agents, and working to understand the molecular basis of drug efficacy.
The primary focus of the Delaney Lab is the development and clinical translation of methodologies for the ex vivo expansion of hematopoietic stem and progenitor cells. In particular, we have focused on methods for the ex vivo expansion of cord blood stem and progenitor cells with the goal of improving outcomes for patients undergoing cord blood transplantation.
Clinical focus is diagnosis and management of benign and malignant hematologic disorders as well as solid tumors. Research includes developing immune-based approaches to prevent and treat relapse of myeloid cancers, including after allogeneic HSCT.
Hematopoietic cell transplantation for severe autoimmune diseases, nonmyeloablative hematopoietic cell transplantation, hematopoietic stem cell and T cell gene therapy and the development of radiation mitigators
The Geraghty laboratory is interested in the genetics of the immune response and the consequential functions of key components. We are examining the essential detail of the genetics and genomics of the immune response in humans and nonhuman primates, detail that differs among individuals and directly affects a plethora of immune interactions and derivative clinical outcomes.
Research is focused on the design and analysis of laboratory research, clinical trials and observational studies in hematopoietic cell transplant (HCT), and in rheumatology, breast cancer, ovarian cancer, as well as a wide variety of large laboratory projects at Fred Hutch and throughout the world.
Developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.
Research is focused on the development, invasion and metastasis of intestinal cancers characterized by chromosome/genetic instability and dysregulated proliferation. Treats patients with cancers of the lung, rectum, small intestines or colon, as well as patients with myeloma and non-Hodgkin's lymphoma.
Research is focused on understanding the factors that control the formation of the hematopoietic stem cells, harnessing technologies to analyze gene activities across the many different cell types within the special hematopoietic stem cell niche and identifying specific biological signals that trigger the formation of blood stem cells to develop a system for generating and cultivating blood stem cells in the lab.
Studies the cellular and molecular dynamics that underlie metastasis, i.e. the spread of cancer cells from a primary tumor to distant organs. The main focus of his lab is the tumor-immune cell interactions that variably promote or defend against metastasis, particularly in lung cancers.
Research and clinical practice involving hematopoietic stem cell transplantation and cancer immunotherapy. Studies address the graft-vs-host disease, opportunistic infection, relapse and graft rejection.
The Hockenbery lab studies programmed cell death (apoptosis) pathways that are defective in many cancer cells; and the role of cancer-cell metabolism in apoptosis, oncogene functions, and environmental/dietary risk factors, including excess supply of nutrients. After identifying cancer-selective targets, they carry out small-molecule screens for inhibitors to identify lead compounds as anticancer agents.
The initial focus was to study the role of inflammatory cell derived proteinases in diseases occurring within the lungs. To date, this has included novel findings for many disease processes including lung cancer, COPD/emphysema, acute lung injury, pulmonary infections, and pulmonary fibrosis. More recently, the focus has shifted to the tumor microenvironment.
Understanding patient barriers and facilitators to colorectal cancer screening, determining factors that influence colonoscopy completion following abnormal stool-based screening tools and identifying gaps in care to implement interventions that improve the quality of cancer control and prevention, particularly in minority populations.
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
Clinical expertise is hematology providing hematopoietic cell transplants to patients with blood disorders. Her research is focused on survivorship issues, quality-of-life and the impact of chronic graft-versus-host-disease.
Treats patients with sarcoma, a rare cancer of the bones and soft tissue, with a focus on GIST (gastrointestinal stromal tumor), intra-abdominal and retroperitoneal tumors and rare, aggressive forms of sarcoma.
Research is focused on androgen and androgen receptor-related mechanisms of resistance that lead to prostate cancer progression. Current areas of research include pathways of intra-tumoral androgen steroidogenesis and metabolism, structural alterations in the androgen receptor, the activity of androgen transport proteins, and how alterations in these and other pathway may influence the sequencing of androgen and chemotherapy treatments. An important goal is to determine how patient and tumor-specific alterations in these proteins may be used to predict response to agents targeting these pathways.
Hematologic malignancies, including leukemias and lymphomas, and tailoring treatment plans to deliver high quality care. Developing radioimmunotherapies that use immune system proteins known as antibodies to selectively target radioactivity to cancer cells, sparing normal tissues.
Studies focus on 1) understanding the roles of distinct T cell subsets in protective immunity to pathogens and tumors and on 2) the development and clinical application of adoptive T cell therapies for viral diseases and cancers, using unmodified and genetically modified antigen-specific T cells.
Studies the very first steps that lead to a productive immune response. These involve circulating “innate” immune cells that initially recognize problems, such as cells infected by a virus or transformed by malignant changes.
Research interests include health services research, where main goal is to understand how patients are treated in the general population (who do not have access to cancer centers) and learning how the most recent advances might be brought to treating these individuals. Also working to design and implement clinical trials that might establish a new, life-saving treatment. Another recent focus is on strategies to harness the immune system in treating virus-associated cancers. Medical oncologist who is board certified in Internal Medicine and in Hematology/Oncology. Specializes in treating patients with lung and head-and-neck cancers, and also has experience in treating patients with breast, gastric and hematologic cancers.
The Program in Transplantation Biology combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation; these include host-versus-graft reactions, graft failure, acute and chronic graft-versus-host disease (GVHD), regimen-related toxicities, and induction of graft-versus-tumor reactions. The program’s goal has been to use stem cell transplantation to treat patients with malignant and nonmalignant hematologic diseases.
The development of cellular therapy for leukemia. Specifically, the development of T-cell therapies that potentially prevent relapse of acute lymphoblastic leukemia in patients who received cord blood transplants.
Determining acute, long term and late complications of cancer treatment for hematopoietic cell transplantation and other cancer survivors, along with clinical trials to improve outcomes during and after cancer treatment
Dr. Triplette has studied racial disparities in coronary artery disease, chronic lung disease in HIV patients, and community-based screening for HIV and lung cancer. His current collaborative studies focus on lung cancer screening practices in underserved and at-risk populations.
Research is focused on the the preclinical and early clinical development and characterization of novel antigen-directed immunotherapies for AML, the conduct of trials testing novel treatments and innovative care approaches for AML patients, and approaches to develop and improve diagnostic and prognostic tools in AML.
Clinical focus is treating patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. Research is focused on cancer immunology, specifically the mechanisms and molecules that mediate graft-versus-host disease and graft-versus tumor.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.